Drug Search Results

Bamosiran

Alternative Names: bamosiran, syl-040012, syl040012, syl 040012
Latest Update: 2024-05-05
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: ADRB2 Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Ocular,Topical,Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sylentis
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bamosiran

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Glaucoma, Open-Angle|Glaucoma|Hypertension

Phase 1: Glaucoma|Hypertension

Trial	Phase	Trial Status	Disease	Primary Completion Date
SYLTAG	P2	Completed	Glaucoma	2015-08-05
SYLTAG	P2	Completed	Hypertension\|Glaucoma, Open-Angle	2015-08-01
SYL040012_III	P2	Completed	Hypertension\|Glaucoma, Open-Angle	2013-05-01
2011-001849-33	P2	Completed	Glaucoma, Open-Angle\|Hypertension	2013-04-30

Recent News Events

Date	Type	Title
05/05/2024	PubMed	Supramolecular Gels Based on C3-Symmetric Amides: Application in Anion-Sensing and Removal of Dyes from Water.
04/23/2024	PubMed	Perioperative outcomes and platinum resistant recurrence in patients undergoing systematic, protocol-based, total parietal peritonectomy during interval cytoreductive surgery for advanced ovarian cancer: results of the TORPEDO study.
03/31/2024	PubMed	Pandemic Risk Assessment for Swine Influenza A Virus in Comparative In Vitro and In Vivo Models.
07/27/2021	News Article	Ocular Hypertension Market Insight, Epidemiology and Market Forecast Report 2021-2030 - ResearchAndMarkets.com
03/31/2021	News Article	Global Ocular Hypertension Pipeline Insight Report 2021 Featuring Nicox, Santen, AbbVie, MediPrint Ophthalmics, Whitecap Biosciences, Ocular Therapeutix, Sylentis, Chong Kun Dang, Aerpio - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions